



## Final Appraisal Recommendation

Advice No: 0312 – February 2012

### Trastuzumab (Herceptin<sup>®</sup>▼)

Limited submission by Roche Products Ltd

#### Recommendation of AWMSG

Trastuzumab (Herceptin<sup>®</sup>▼) is recommended as an option for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. This submission covers the licence extensions for treatment with trastuzumab:

- following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel;
- in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.

**AWMSG is of the opinion that trastuzumab (Herceptin<sup>®</sup>▼) is suitable for specialist only prescribing within NHS Wales for the above indication.**

#### Additional notes:

- The licence extension for the above indication allows concomitant use of trastuzumab (Herceptin<sup>®</sup>▼) with chemotherapy. It does not change the dose or treatment duration of trastuzumab (Herceptin<sup>®</sup>▼). There is no additional budget impact anticipated as a result of this licence extension when compared with the current practice of administering trastuzumab (Herceptin<sup>®</sup>▼) sequentially after chemotherapy. A limited submission was therefore considered appropriate.
- A patient organisation submission was not actively sought.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available) and discussions at AWMSG.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Marketing authorisation holder on first issue:	Roche Products Ltd
Date of first issue	February 2012
Last reviewed	August 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0312:  
Trastuzumab (Herceptin<sup>®</sup>▼). February 2012.